

Callitas Health Inc

00:04 26 Jul 2018

Callitas Health awarded US patent for male infertility treatment, extending its ToConceive brand

Cincinnati-based Callitas Health Inc (CSE:LILY, OTCQB:MPHMF, OTCMKTS: MPHMF) announced Wednesday that its treatment for male infertility received a patent from the United States Patent and Trademark Office.

The health and wellness company said it was granted US Patent No. 10,004,697 for its In Vivo Sperm Selection for treating male Infertility.

The patent essentially expands the company's intellectual property portfolio while extending the patent-protected formula and uses of its ToConceive product when treating male infertility (or sub-fertility) caused by reduced functional sperm count in the male partner.

"Male infertility (or sub-fertility) has not received the attention it should," said Callitas Health CEO James Thompson. "Statistics indicate nearly two-thirds of all infertility challenges are linked back to the man and can be further challenged by a lack of lubrication from the woman," he added.

BIG PICTURE: Callitas Health banks on CannaStrips and OTC products while swinging for the fence with blockbuster drugs
The CEO said the full grant of the patent advanced the company's mission to help couples trying to conceive, whether they're dealing "with male or female infertility or a combination of the two."

"This patent grant strengthens the core intellectual property assets of our ToConceive brand and reinforces Callitas' commitment to female sexual health and wellness, as well as male infertility (subfertility), and aiding couples trying to conceive," said Thompson.

Callitas Health has launched ToConceive in North America for couples struggling to conceive a child. It was developed by well-known gynecologic surgeon and infertility specialist Dr Ronald Thompson (father of CEO James Thompson), based on the science behind the 2010 Nobel Prize in Medicine for in vitro fertilization (IVF) and sperm capacitation.


It's FDA-cleared and clinically proven to increase a woman's own natural conception lubrication, called transudate.

Callitas Health is developing remedies across five silos: OTC sexual health & wellness, prescriptions for female sexual health, weight management, cannabis delivery technologies and orphan drugs.

Contact Uttara Choudhury at uttara@proactiveinvestors.com
Follow her on Twitter: @UttaraProactive

Market Cap: \$0.00

1 Year Share Price Graph



Share Information

Code: LILY

Listing: CSE

52 week High Low
0.12 0.09

Sector: Pharma & Biotech

Website: www.callitas.com

Company Synopsis:

Founded on Midwest values, our Cincinnati-based company is people-focused, always looking for ways to benefit our customers, shareholders, and employees. Our company was built on strong work ethic, honesty, and a desire to help others. Our number one goal is helping people by bringing products to market that improve quality of life.

action@proactiveinvestors.com.au

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Callitas Health Inc named herein, including the promotion by the Company of Callitas Health Inc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).